Targeting Truncated RXRα for Cancer Therapy

Overview

Journal Acta Biochim Biophys Sin (Shanghai)

Specialties Biochemistry
Biophysics

Date 2015 Oct 24

PMID 26494413

Citations 9

Authors

Xiaokun Zhang

Hu Zhou

Ying Su

Affiliations

Soon will be listed here.

Abstract

Retinoid X receptor-alpha (RXRα), a unique member of the nuclear receptor superfamily, is a well-established drug target, representing one of the most important targets for pharmacologic interventions and therapeutic applications for cancer. However, how RXRα regulates cancer cell growth and how RXRα modulators suppress tumorigenesis are poorly understood. Altered expression and aberrant function of RXRα are implicated in the development of cancer. Previously, several studies had demonstrated the presence of N-terminally truncated RXRα (tRXRα) proteins resulted from limited proteolysis of RXRα in tumor cells. Recently, we discovered that overexpression of tRXRα can promote tumor growth by interacting with tumor necrosis factor-alpha-induced phosphoinositide 3-kinase and NF-κB signal transduction pathways. We also identified nonsteroidal anti-inflammatory drug Sulindac and analogs as effective inhibitors of tRXRα activities via a unique binding mechanism. This review discusses the emerging roles of tRXRα and modulators in the regulation of cancer cell survival and death as well as inflammation and our recent understanding of tRXRα regulation by targeting the alternate binding sites on its surface.

Citing Articles

Celastrol-regulated gut microbiota and bile acid metabolism alleviate hepatocellular carcinoma proliferation by regulating the interaction between FXR and RXRα and .

Zeng D, Zhang L, Luo Q Front Pharmacol. 2023; 14:1124240.

PMID: 36874033 PMC: 9975715. DOI: 10.3389/fphar.2023.1124240.

Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.

Kim M, Kim M, Salloum S, Qian T, Wong L, Xu M Hepatol Commun. 2022; 6(9):2581-2593.

PMID: 35712812 PMC: 9426409. DOI: 10.1002/hep4.1991.

Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs.

Li F, Song C, Zhang Y, Wu D Acta Biochim Biophys Sin (Shanghai). 2022; 54(1):12-24.

PMID: 35130630 PMC: 9909358. DOI: 10.3724/abbs.2021001.

The role of resveratrol, Sirtuin1 and RXRα as prognostic markers in ovarian cancer.

Chen F, Kolben T, Meister S, Czogalla B, Kolben T, Hester A Arch Gynecol Obstet. 2021; 305(6):1559-1572.

PMID: 34870752 PMC: 9166836. DOI: 10.1007/s00404-021-06262-w.

Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling.

Ye X, Wu H, Sheng L, Liu Y, Ye F, Wang M Nat Commun. 2019; 10(1):1463.

PMID: 30931933 PMC: 6443775. DOI: 10.1038/s41467-019-09375-8.

References

Yen W, Prudente R, Corpuz M, Negro-Vilar A, Lamph W . A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006; 94(5):654-60. PMC: 2361207. DOI: 10.1038/sj.bjc.6602995. View

Yamaoka T, Yan F, Cao H, Hobbs S, Dise R, Tong W . Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc Natl Acad Sci U S A. 2008; 105(33):11772-7. PMC: 2575333. DOI: 10.1073/pnas.0801463105. View

Wang Z, Chen L, Chen J, Zheng J, Gao W, Zeng Z . Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation. Eur J Med Chem. 2013; 62:632-48. PMC: 3738195. DOI: 10.1016/j.ejmech.2013.01.012. View

Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M . Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 2006; 97(10):1044-9. PMC: 11160060. DOI: 10.1111/j.1349-7006.2006.00277.x. View

Jong L, Lehmann J, Hobbs P, Harlev E, Huffman J, Pfahl M . Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity. J Med Chem. 1993; 36(18):2605-13. DOI: 10.1021/jm00070a003. View

Hendry L, John S . Regulation of STAT signalling by proteolytic processing. Eur J Biochem. 2004; 271(23-24):4613-20. DOI: 10.1111/j.1432-1033.2004.04424.x. View

Marone R, Cmiljanovic V, Giese B, Wymann M . Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2007; 1784(1):159-85. DOI: 10.1016/j.bbapap.2007.10.003. View

Jiang S, Shen S, Shyu R, Yu J, Harn H, Yeh M . Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization. Br J Cancer. 1999; 80(1-2):206-14. PMC: 2362992. DOI: 10.1038/sj.bjc.6690340. View

Brabender J, Danenberg K, Metzger R, Schneider P, Lord R, Groshen S . The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer. Clin Cancer Res. 2002; 8(2):438-43. View

10.

Sun M, Yang L, Feldman R, Sun X, Bhalla K, Jove R . Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003; 278(44):42992-3000. DOI: 10.1074/jbc.M306295200. View

11.

Holmes W, Soprano D, Soprano K . Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J Biol Chem. 2002; 277(47):45408-19. DOI: 10.1074/jbc.M204600200. View

12.

Narayanan N, Narayanan B, Reddy B . A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol. 2005; 26(3):785-92. View

13.

Aguirre R, Karpen S . Inflammatory mediators increase SUMOylation of retinoid X receptor α in a c-Jun N-terminal kinase-dependent manner in human hepatocellular carcinoma cells. Mol Pharmacol. 2013; 84(2):218-26. PMC: 3716323. DOI: 10.1124/mol.113.085555. View

14.

Huang J, Powell W, Khodavirdi A, Wu J, Makita T, Cardiff R . Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res. 2002; 62(16):4812-9. View

15.

Leis H, Page A, Ramirez A, Bravo A, Segrelles C, Paramio J . Glucocorticoid Receptor Counteracts Tumorigenic Activity of Akt in Skin through Interference with the Phosphatidylinositol 3-Kinase Signaling Pathway. Mol Endocrinol. 2003; 18(2):303-11. DOI: 10.1210/me.2003-0350. View

16.

Lin B, Kolluri S, Lin F, Liu W, Han Y, Cao X . Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004; 116(4):527-40. DOI: 10.1016/s0092-8674(04)00162-x. View

17.

Smith B, Wilson L . Management of mycosis fungoides: Part 2. Treatment. Oncology (Williston Park). 2003; 17(10):1419-28. View

18.

Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T . Expression of retinoid X receptor alpha is decreased in 3'-methyl-4-dimethylaminoazobenzene-induced hepatocellular carcinoma in rats. Oncol Rep. 2007; 18(4):879-84. View

19.

Pincheira R, Castro A, Ozes O, Idumalla P, Donner D . Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J Immunol. 2008; 181(2):1288-98. DOI: 10.4049/jimmunol.181.2.1288. View

20.

Zhang H, Zhou R, Li L, Chen J, Chen L, Li C . Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. J Biol Chem. 2010; 286(3):1868-75. PMC: 3023482. DOI: 10.1074/jbc.M110.166215. View